Woodside Kenneth J, Lick Scott D
Division of Cardiothoracic Surgery, Department of Surgery, University of Texas Medical Branch, Galveston, Texas 77555-0528, USA.
J Heart Lung Transplant. 2007 Jul;26(7):750-2. doi: 10.1016/j.healun.2007.04.012.
We report the case of a heart transplant recipient who presented twice in profound cardiogenic shock at Months 4 and 8 post-transplant. She had unsuccessful conventional rejection therapy, but responded dramatically to alemtuzumab salvage therapy. Both times, her recovery onset was strikingly parallel to that described after using alemtuzumab as salvage therapy in renal transplantation. The reported use of alemtuzumab in thoracic organ transplant is rare. We believe this is the first reported case of alemtuzumab as salvage therapy in heart transplantation.
我们报告了一例心脏移植受者的病例，该患者在移植后第4个月和第8个月两次出现严重的心源性休克。她接受传统的抗排斥治疗未成功，但对阿仑单抗挽救治疗反应显著。两次治疗时，她的恢复起始情况与肾移植中使用阿仑单抗作为挽救治疗后的情况惊人地相似。文献报道阿仑单抗在胸器官移植中的应用很少。我们认为这是首例报道使用阿仑单抗作为心脏移植挽救治疗的病例。
